

Original Research Article

Evaluation of Antidiabetic Activity of Polyherbal Formulation “*Vasant Kusumakar Ras*” on Alloxan-induced and Dexamethasone-induced Diabetic Rats

Running title: Antidiabetic Activity of *Vasant Kusumakar Ras*

ABSTRACT

Aim: The current study observed the antidiabetic effect of *Vasant Kusumakar Ras*, an Ayurvedic polyherbal formulation, in alloxan-induced and dexamethasone-induced diabetic rats.

Materials and Methods: Alloxan (120 mg/kg, i.p.) and dexamethasone sodium phosphate (5 mg/kg, i.p.) were used to induce diabetes in rats. The oral antidiabetic activity of *Vasant Kusumakar Ras* was evaluated by single doses of *Vasant Kusumakar Ras* (400 and 600 mg/kg, p.o.) in albino rats during a 10-day treatment period, with the effect of the *Vasant Kusumakar Ras* on blood glucose levels and serum lipid parameters measured on 0, 7th, and 11th day. Glibenclamide (5 mg/kg, p.o.) was used as the reference drug.

Results: In alloxan-induced diabetic rats, the elevated levels of blood glucose significantly ($p < 0.05$) decreased after oral administration of *Vasant Kusumakar Ras* (400 mg/kg and 600 mg/kg), and Glibenclamide (5 mg/kg). When compared to the disease control group, treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days reduced total cholesterol significantly ($p < 0.001$). Treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days, significantly ($p < 0.001$) decreased LDL level when compared to the disease control group. In dexamethasone-induced diabetic rats, all rats given with dexamethasone and *Vasant Kusumakar Ras* (400 mg/kg and 600 mg/kg) showed a significant ($p < 0.05$) decrease in the level of blood glucose when compared with disease control rats. The rats treated with dexamethasone and Glibenclamide showed a significant ($p < 0.05$) decrease in blood glucose level when compared to disease control rats. When compared to the disease control group, treatment with *Vasant Kusumakar Ras* and Glibenclamide (5 mg/kg) for 10 days reduced total cholesterol significantly ($p < 0.001$). Treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days, significantly ($p < 0.001$) decreased LDL level when compared to the disease control group.

Conclusion: *Vasant Kusumakar Ras* was shown to have stronger antidiabetic activity and it also improves the lipid metabolism in both alloxan-induced and dexamethasone-induced diabetic rats.

Keywords: Polyherbal formulation; *Vasant Kusumakar Ras*; alloxan; dexamethasone; antidiabetic

1. INTRODUCTION

Diabetes mellitus is one of the most common diseases, affecting over 6% of the global population, and the diabetes dynamics are changing speedily in low- and middle-income nations [1]. According to International Diabetes Federation's (IDF) estimates, 80% of the world's diabetes population would come from low- and middle-income nations in 2030 [2]. Diabetes is one of the six leading causes of death worldwide, as well as a source of numerous systemic problems. Insulin therapy or glucose-lowering medicines such as alpha-glucosidase inhibitors, biguanides, sulfonylureas, and thiazolidinediones are used to treat diabetes mellitus. One of the challenges in the treatment of any systemic condition is the development of an adverse event; as a result, numerous research institutes and pharmaceutical companies are active in drug development to uncover molecules with strong therapeutic potential and fewer adverse events [3-4]. The World Health Organization expert committee on Diabetes has recommended that traditional systems of medicine should be supported for the prevention and management of diabetic complications. This is especially true when mainstream pharmacotherapy is ineffective [5]. *Vasant Kusumakar Ras* is a well-known polyherbal formulation used to treat diabetes and its symptoms around the world [6]. According to the Ayurvedic literature, *Vasant Kusumakar Ras* possess *Pramehgana* (anti-diabetic), *Ojovardhak*, and *Rasayana* (improves immunity, rejuvenator) characteristics and so may play a protective role in diabetes [7]. The goal of this study was to confirm the antidiabetic activity of *Vasant Kusumakar Ras* in alloxan and dexamethasone-induced diabetic rats.

2. MATERIALS AND METHODS

2.1 Chemicals

Glibenclamide tablet (Aventis Pharma Ltd., Mumbai, India); dexamethasone sodium phosphate (Tridoss Laboratories Ltd., Mumbai, India); alloxan (Sigma-Aldrich, USA); glucose estimation kit. (Span diagnostic Ltd., Surat, India), cholesterol and LDL estimation kits (Agappe Diagnostics, Kerala) were used in this study. All the other reagents and chemicals used in this study were of analytical grade.

2.2 Preparation of *Vasant Kusumakar Ras* formulation

Vasant Kusumakar Ras polyherbal formulation is manufactured by DABUR INDIA LTD. Company, a manufacturer and exporter of herbal ayurvedic goods. *Vasant Kusumakar Ras* formulation was made as per the ayurvedic text *Yogratnakar – Prameha chikit sanadhaya* as follows:

Two parts of *Rajat bhasma* and *Swarna bhasma*, Three parts each of *Kanta Loha bhasma*, *Vangabhasma*, Four parts of *Abhrak bhasma*, *Parad bhasma*, *Praval* and *Mauktik*.

The above ingredients were processed and trituration was given 7 times separately with each of the following ingredients:

Cow milk, *Ikshu Ras* (*Saccharum officinarum*), *Vasa* (*Adhatoda vasica* Nees.), *Kamal* (*Nelumbium speciosum* Willd), *Jalavetas* (*Salix tetrasperma* Roxb), *Haridra* (*Curcuma longa* Linn.), *Kadalikanda* (*Musa sapientum* Linn.) and one bhavana of Rose (*Rosa centifolia* Linn.), *Malati* (*Jasminum grandiflorum* Linn.) and *Kastuti* (Musk) (either of these juices).

The formulation was developed in the tablet dosage form.

2.3 Animals

Adult Wistar rats (170 ± 20 g) of either sex were obtained from Central Drug Research Institute, Lucknow, India. The animals were housed in huge, spacious polypropylene cages at an ambient room temperature with a 12-h light/12-h dark cycle. Rats had free access to water and a standard normal pellet diet. The study was approved by the Institutional Animal Ethics Committee (CPCSEA1087/07) of the Hygia Institute of Pharmaceutical Education and Research, Lucknow (Hygia/M. Pharm/24/2012-13), and all the animal experiments were carried out according to the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines, Ministry of Environment and Forests, Government of India.

2.4. Induction of experimental diabetes in alloxan-induced model and experimental design

Diabetes was induced in 24-h fasted Wistar rats by a single intraperitoneal (i.p.) injection of alloxan (120 mg/kg) in 0.9% saline. Four hours after alloxan administration, drinking water was replaced with a 10% glucose solution, for the next 24 hours to prevent catastrophic hypoglycemia caused by enormous insulin release from the necrosing pancreatic β-cells. On the third day, the diabetes was confirmed by a blood glucose level (BGL) assessment. Diabetic animals were defined as those with blood glucose levels greater than 13.88 mmol/L (>250 mg/dL) and were included in the study [8]. The animals were divided into five groups of six animals in each group. Groups 1 received only 0.9% saline. Groups 2 received only alloxan (120 mg/kg, i.p.). Group 3 received Glibenclamide (5 mg/kg, p.o.) which served as the reference standard group. Polyherbal formulation at the doses, 400 and 600 mg/kg was administered orally to the rats of groups 4 and 5, respectively (Table 1). The blood glucose concentrations of the animals were measured at the beginning of the study on day 0 and measurements were repeated on the 7th and 11th days.

Table 1: Administration of *Vasant Kusumakar Ras* and Glibenclamide in the alloxan-induced model in rats

S. No.	Group	Treatment
1	Group 1	Control (0.9% Normal saline)
2	Group 2	Kept as a negative control, i.e., treated with alloxan (120 mg/kg, i.p.)
3	Group 3	Treated with standard oral hypoglycemic drug, i.e., Glibenclamide (5 mg/kg, p.o.) + alloxan (120 mg/kg, i.p.).
4	Group 4	Treated orally with 400 mg/kg <i>Vasant Kusumakar Ras</i> + alloxan (120 mg/kg, i.p.)

5	Group 5	Treated orally with 600 mg/kg <i>Vasant Kusumakar Ras</i> + alloxan (120 mg/kg, i.p.)
---	---------	---

2.5. Induction of experimental diabetes in dexamethasone-induced model and experimental design

The animals were divided into five groups of six animals in each group. Groups 1 received only 0.9% saline. Groups 2 received only dexamethasone sodium phosphate (5 mg/kg, i.p.). Group 3 received Glibenclamide (5 mg/kg, p.o.) which served as the reference standard group. Polyherbal formulation at the doses, 400 and 600 mg/kg was administered orally to the rats of groups 4 and 5, respectively (Table 2). All the treatments were made for 10 days. One hour after the test drug administration all the rats received dexamethasone (5 mg/kg, p.o.) daily for 10 days except group 1 which served as the normal control group [9]. The blood glucose concentrations of the animals were measured at the beginning of the study on day 0 and measurements were repeated on the 7th and 11th day after 1 h post dexamethasone treatment.

Table 2: Administration of *Vasant Kusumakar Ras* and Glibenclamide in the dexamethasone-induced model in rats

S. No.	Group	Treatment
1	Group 1	Control (0.9% Normal saline)
2	Group 2	Kept as a negative control, i.e., treated with dexamethasone sodium phosphate (5 mg/kg, i.p.)
3	Group 3	Treated with standard oral hypoglycemic drug, i.e., Glibenclamide (5 mg/kg, p.o.) + Dexamethasone sodium phosphate (5 mg/kg, i.p.)
4	Group 4	Treated orally with 400 mg/kg <i>Vasant Kusumakar Ras</i> + Dexamethasone sodium phosphate (5 mg/kg, i.p.)
5	Group 5	Treated orally with 600 mg/kg <i>Vasant Kusumakar Ras</i> + Dexamethasone sodium phosphate (5 mg/kg, i.p.)

2.6. Biochemical analysis

At the end of the experimental period (on the 11th day), rats were anesthetized under mild ether anesthesia; and blood was withdrawn from the retro-orbital plexus. Glucose levels were measured in blood samples. Blood was centrifuged at 4000 g for 10 min., subsequently, serum was separated and kept at -20 °C until further investigation. Standard commercial kits (Agappe Diagnostics, Kerala) were used to estimate cholesterol (total cholesterol) and LDL (low-density lipoprotein) in serum.

2.7 Statistical analysis

Data were expressed as Mean ± S.E.M. Statistical significance between the groups was tested using one-way ANOVA, followed by Dunnett's Multiple Comparison Test. Results were considered significant, when p values were less than 0.05 (*p < 0.05).

3. RESULTS

3.1 Effect of *Vasant Kusumakar Ras* on blood glucose level in alloxan-induced diabetic rats

Alloxan causes the selective damage of β cells of islets of the pancreas, resulting in a rise in blood glucose levels. Alloxan administration at a dose of 120 mg/kg body weight generates a strong diabetogenic response in albino rats, according to the results of this study (Fig. 1). Blood glucose levels were assessed randomly on the 0, 7th, and 11th days of study. The elevated levels of blood glucose significantly ($p < 0.05$) decreased after oral administration of *Vasant Kusumakar Ras* (400 mg/kg and 600 mg/kg), and Glibenclamide (5 mg/kg). If blood glucose levels are the main metric, *Vasant Kusumakar Ras* and Glibenclamide were both highly effective in inducing a strong antihyperglycemic response in rats. Though all two doses of formulations produced equivalent antihyperglycemic activity to Glibenclamide in terms of relative efficacy, *Vasant Kusumakar Ras* 400 mg/kg was shown to have stronger antihyperglycemic activity than *Vasant Kusumakar Ras* 600 mg/kg.




Fig. 1: Effect of *Vasant Kusumakar Ras* and Glibenclamide on blood glucose level in alloxan-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; *significant difference ($p < 0.05$) with respect to diabetic control.

3.2 Effect of *Vasant Kusumakar Ras* on the total cholesterol level in alloxan-induced diabetic rats

The serum total cholesterol of disease control group rats increased significantly on the 11th day as compared to normal control group rats. When compared to the disease control group, treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days reduced total cholesterol significantly ($p < 0.001$) (Fig. 2). Though all two doses of formulations demonstrated equivalent serum cholesterol-lowering activity to Glibenclamide (5 mg/kg), *Vasant Kusumakar Ras* 400 mg/kg has been proven to have higher serum cholesterol-lowering activity than *Vasant Kusumakar Ras* 600 mg/kg in terms of relative efficacy.




Fig. 2: Effect of *Vasant Kusumakar Ras* and Glibenclamide on the total cholesterol level in alloxan-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; ***significant difference ($p < 0.001$) with respect to diabetic control.

3.3 Effect of *Vasant Kusumakar Ras* on LDL level in alloxan-induced diabetic rats

On the 11th day, there was a significant increase in serum LDL level of disease control group rats, as compared to normal control group rats. Treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days, significantly ($p < 0.001$) decreased LDL level when compared to the disease control group (Fig. 3). Though all two doses of formulations demonstrated equivalent serum LDL lowering activity to Glibenclamide (5 mg/kg), *Vasant Kusumakar Ras* 400 mg/kg has been proven to have stronger serum LDL lowering activity than *Vasant Kusumakar Ras* 600 mg/kg in terms of relative efficacy.




Fig. 3: Effect of *Vasant Kusumakar Ras* and Glibenclamide on LDL level in alloxan-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; ***significant difference ($p < 0.001$) with respect to diabetic control.

3.4 Effect of *Vasant Kusumakar Ras* on blood glucose level in dexamethasone-induced diabetic rats

Blood glucose levels were assessed randomly on the 0, 7th, and 11th days of study. When comparing the disease control group to the normal control group, there was a significant increase in blood glucose levels. All rats given with dexamethasone and *Vasant Kusumakar Ras* (400 mg/kg and 600 mg/kg) showed a significant decrease ($p < 0.05$) in the level of blood glucose when compared with disease control rats (Fig. 4). The rats treated with dexamethasone and Glibenclamide showed a significant ($p < 0.05$) decrease in blood glucose level when compared to disease control rats. On the 11th day, *Vasant Kusumakar Ras* 400 mg/kg was found to have stronger antihyperglycemic activity than *Vasant Kusumakar Ras* 600 mg/kg, even though all two doses of formulations produced comparable antihyperglycemic activity to Glibenclamide (5 mg/kg). The *Vasant Kusumakar Ras* has a considerable effect on dexamethasone-induced insulin resistance, according to the findings.




Fig. 4: Effect of *Vasant Kusumakar Ras* and Glibenclamide on blood glucose level in dexamethasone-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; *significant difference ($p < 0.05$) with respect to diabetic control.

3.5 Effect of *Vasant Kusumakar Ras* on the total cholesterol level in dexamethasone-induced diabetic rats

The serum total cholesterol of disease control group rats increased significantly on the 11th day as compared to normal control group rats. When compared to the disease control group, treatment with *Vasant Kusumakar Ras* and Glibenclamide (5 mg/kg) for 10 days reduced total cholesterol significantly ($p < 0.001$) (Fig. 5). Though all two doses of formulations generated equivalent serum cholesterol-lowering activity to Glibenclamide in terms of relative efficacy, *Vasant*

Kusumakar Ras 600 mg/kg was shown to have higher serum cholesterol-lowering action than *Vasant Kusumakar Ras* 400 mg/kg.




Fig. 5: Effect of *Vasant Kusumakar Ras* and Glibenclamide on the total cholesterol level in dexamethasone-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; ***significant difference ($p < 0.001$) with respect to diabetic control.

3.6 Effect of *Vasant Kusumakar Ras* on LDL level in dexamethasone-induced diabetic rats

On the 11th day, there was a significant increase in serum LDL level of disease control group rats, as compared to normal control group rats. Treatment with *Vasant Kusumakar Ras* and Glibenclamide for 10 days, significantly ($p < 0.001$) decreased LDL level when compared to the disease control group (Fig. 6). As far as the relative efficacy is concerned, though all the two doses of formulations produced comparable serum LDL lowering activity to Glibenclamide (5 mg/kg), *Vasant Kusumakar Ras* 600 mg/kg has been proven the higher serum LDL lowering activity than *Vasant Kusumakar Ras* 400 mg/kg.




Fig. 6: Effect of *Vasant Kusumakar Ras* and Glibenclamide on LDL level in dexamethasone-induced diabetic rats. Data are expressed as Mean \pm S.E.M.; ***significant difference ($p < 0.001$) with respect to diabetic control.

4. DISCUSSION

Diabetes mellitus is a metabolic condition characterized by a lack of endogenous insulin secretion or activity, hyperglycemia, and an unknown cause [10]. Diabetes mellitus is a multifactorial disease characterized by flaws in reactive oxygen species (ROS) scavenging enzymes [11], hyperglycemia [12], lipoprotein abnormalities [13], a high basal metabolic rate [14], and a high level of oxidative stress-induced damage [15]. In rodents, diabetes is caused by injecting alloxan, which induces diabetes while also producing ROS, resulting in pancreatic β -cell destruction [16]. Chronic hyperglycemia is the leading cause of a variety of long-term diabetic problems.

In the present study, the antidiabetic effect of *Vasant Kusumakar Ras* was evaluated in alloxan-induced diabetic rats. *Vasant Kusumakar Ras* and Glibenclamide treatment for 10 days reduced raised blood glucose levels, which were observed to be high in diabetic control rats. *Vasant Kusumakar Ras* 400 mg/kg showed the greatest reduction in blood glucose levels. *Vasant Kusumakar Ras*, therefore, demonstrated antidiabetic action in diabetic rats that were comparable to that of standard drug. Glibenclamide has also been proven to help with lipid profile improvement, mostly by correcting aberrant glucose metabolism. *Vasant Kusumakar Ras* and glibenclamide dramatically reduced serum cholesterol levels, according to the findings.

Steroids are medications that have been widely utilized to treat a range of ailments. Glucocorticoids, despite being frequently recommended for their anti-inflammatory and immunosuppressive characteristics, have several adverse effects, with hyperglycemia being one of the most common and prominent. Increased hepatic glucose synthesis and insulin resistance in peripheral tissues contribute to glucocorticoid-induced hyperglycemia [17]. Insulin secretion has also been demonstrated to be suppressed by glucocorticoids. *Vasant Kusumakar Ras* at a dose of 600 mg/kg significantly lowered blood glucose levels in dexamethasone-induced diabetic rats after 10 days of treatment when compared to the diabetic control group. *Vasant Kusumakar Ras*-treated groups had significantly lower total cholesterol and LDL levels than the dexamethasone-

induced group, suggesting that *Vasant Kusumakar Ras* may play a role in decreasing hyperglycemia.

Other investigations have found that dexamethasone-induced hyperglycemia causes an increase in total cholesterol and LDL levels. *Vasant Kusumakar Ras*, a polyherbal preparation, has a therapeutic benefit by significantly lowering the LDL fraction. Glibenclamide was chosen as the positive control to evaluate the effectiveness of the model in our study because it is thought to decrease insulin resistance in the presence of insulin [18].

5. CONCLUSION

The present findings showed that *Vasant Kusumakar Ras*, a polyherbal preparation has anti-diabetic potential. *Vasant Kusumakar Ras* showed a significant antidiabetic effect in albino rats at 400 and 600 mg/kg, and this effect was comparable to that of glibenclamide. The biochemical analysis supports the anti-diabetic effectiveness of the polyherbal formulation. *Vasant Kusumakar Ras* treatment improved the serum lipid profile which was altered in diabetic rats.

CONSENT

It is not applicable

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. *Annals of the New York academy of sciences*. 2006;1084(1):1-29.
2. Petchi RR, Parasuraman S, Vijaya C. Antidiabetic and antihyperlipidemic effects of an ethanolic extract of the whole plant of *Tridax procumbens* (Linn.) in streptozotocin-induced diabetic rats. *Journal of basic and clinical pharmacy*. 2013;4(4):88-92.
3. Parasuraman S, Kumar EP, Kumar A, Emerson SF. Free radical scavenging property and diuretic effect of triglize, a polyherbal formulation in experimental models. *Journal of pharmacology & Pharmacotherapeutics*. 2010;1(1):38-41.
4. Petchi RR, Vijaya C, Parasuraman S. Antidiabetic activity of polyherbal formulation in streptozotocin–nicotinamide induced diabetic Wistar rats. *Journal of traditional and complementary medicine*. 2014;4(2):108-17.
5. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP. Indian herbs and herbal drugs used for the treatment of diabetes. *Journal of clinical biochemistry and nutrition*. 2007;40(3):163-73.
6. Tamoli SM, Kohli KR, Kaikini AA, Muke SA, Shaikh AA, Sathaye S. Vasant Kusmakar Ras, an ayurvedic herbo-mineral formulation prevents the development of diabetic retinopathy in rats. *Journal of Ayurveda and integrative medicine*. 2020;11(3):270-6.
7. Sridharan K, Mohan R, Ramaratnam S, Panneerselvam D. Ayurvedic treatments for diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2011(12): CD008288.
8. Shah NA, Khan MR. Antidiabetic effect of *Sida cordata* in alloxan induced diabetic rats. *BioMed research international*. 2014;2014: ID 671294. <https://doi.org/10.1155/2014/671294>
9. Rajasekaran S, Jaykar B, Anandan R, Aboobacker KP, Vannamalar S. Anti-diabetic activity of leaves of *Zizyphus nummularia* by dexamethasone induced diabetic rat model. *Int J PharmTech Res*. 2013;5(2):844-51.
10. Paik SG, Blue ML, Fleischer N, Shin SI. Diabetes susceptibility of BALB/cBOM mice treated with streptozotocin: inhibition by lethal irradiation and restoration by splenic lymphocytes. *Diabetes*. 1982;31(9):808-15.

11. Kesavulu MM, Giri R, Rao K, Apparao CH. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. *Diabetes & metabolism*. 2000;26(5):387-92.
12. Ugochukwu NH, Babady NE, Cobourne M, Gasset SR. The effect of *Gongronema latifolium* extracts on serum lipid profile and oxidative stress in hepatocytes of diabetic rats. *Journal of biosciences*. 2003;28(1):1-5.
13. Scoppola A, Montecchi FR, Menzinger G, Lala A. Urinary mevalonate excretion rate in type 2 diabetes: role of metabolic control. *Atherosclerosis*. 2001;156(2):357-61.
14. Owu DU, Antai AB, Udofia KH, Obembe AO, Obasi KO, Eteng MU. Vitamin C improves basal metabolic rate and lipid profile in alloxan-induced diabetes mellitus in rats. *Journal of Biosciences*. 2006;31(5):575-9.
15. Ahmed AB, Rao AS, Rao MV. In vitro callus and in vivo leaf extract of *Gymnema sylvestre* stimulate β -cells regeneration and anti-diabetic activity in Wistar rats. *Phytomedicine*. 2010;17(13):1033-9.
16. Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozocin-and alloxan-induced H₂O₂ generation and DNA fragmentation in pancreatic islets: H₂O₂ as mediator for DNA fragmentation. *Diabetes*. 1991;40(9):1141-5.
17. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. *World journal of diabetes*. 2015;6(8):1073-81.
18. Rajasekaran S, Jaykar B, Anandan R, Aboobacker KP, Vannamalar S. Anti-diabetic activity of leaves of *Zizyphus nummularia* by dexamethasone induced diabetic rat model. *Int J PharmTech Res*. 2013;5(2):844-51.